• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

    5.180 -0.090 (-1.71%)
    Streaming Delayed Price Updated: 12:21 PM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 172,588
    Open 5.340
    Bid (Size) 5.180 (400)
    Ask (Size) 5.210 (400)
    Prev. Close 5.270
    Today's Range 5.180 - 5.454
    52wk Range 4.680 - 50.40
    Shares Outstanding 58,102,949
    Dividend Yield 278.38%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -67.6%
    -67.6%
    1 Month
    -7.5%
    -7.5%
    3 Month
    -46.5%
    -46.5%
    6 Month
    -64.6%
    -64.6%
    1 Year
    -83.0%
    -83.0%

    More News

    Read More
    News headline image
    LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗
    Via Chartmill
    LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗
    Via Chartmill
    News headline image
    Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance
    News headline image
    Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    LENZ Therapeutics to Participate in Upcoming Investor Conferences
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗
    Via The Motley Fool
    News headline image
    Why Lenz Therapeutics Stock Crashed Today ↗
    Via The Motley Fool
    News headline image
    LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗
    Via Benzinga
    News headline image
    LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics to Present at Upcoming Investor Conferences
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is LENZ Therapeutics, Inc. - Common Stock publicly traded?
    Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?
    LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?
    The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market
    What is the current price of LENZ Therapeutics, Inc. - Common Stock?
    The current price of LENZ Therapeutics, Inc. - Common Stock is 5.180
    When was LENZ Therapeutics, Inc. - Common Stock last traded?
    The last trade of LENZ Therapeutics, Inc. - Common Stock was at 08/06/26 12:21 PM ET
    What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?
    The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 300.97M
    How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?
    LENZ Therapeutics, Inc. - Common Stock has 301M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.